Amgen Inc., the world’s largest biotechnology company, won U.S. antitrust clearance Friday to complete its $9.6-billion purchase of Immunex Corp., maker of a leading rheumatoid arthritis drug. Amgen ...

Amgen Inc., the world’s largest biotechnology company, is in talks to buy rival Immunex Corp. for about $17 billion in cash and stock, people familiar with the negotiations said Thursday. The deal, if ...

Amgen Inc. will announce today that it is acquiring biotechnology rival Immunex Corp. for slightly less than $29 a share in cash and stock, or about $16 billion, according to sources familiar with the ...

NEW YORK – Amgen Inc. said on Monday it plans to buy smaller rival Immunex Corp., maker of rheumatoid arthritis drug Enbrel, for about $16 billion in cash and stock in the largest-ever biotechnology ...

Last week, the Federal Circuit denied Sandoz’s petition for an en banc rehearing of its precedential July 1st panel decision upholding two of Immunex’s patents covering Enbrel®. As explained in the ...

The era of the multibillion-dollar biotechnology deal arrived yesterday when Amgen Inc. said it would pay about $16 billion in cash and stock for Immunex Corp., aiming to create the first biotech ...

SAN FRANCISCO — Biotechnology market leader Amgen Inc. is buying Seattle rival Immunex Corp. for $16 billion in stock and cash in a deal that will add a blockbuster arthritis drug and two other best ...

NEW YORK --Amgen Inc (NASDAQ:AMGN), the world's largest biotechnology company, on Monday said it was buying smaller rival and leading arthritis drug maker Immunex Corp. (NASDAQ:IMNX) for $16 billion ...

When Immunex Corp.'s cancer drug, Leukine, received approval from the Food and Drug Administration in 1991, the company strung together letters to make a sign in the windows of its downtown ...